Answers are grounded in this paper and cite their sources.
Potential conflict of interest: Nothing to report. Abbreviation ELAD extracorporeal cellular therapy TO THE EDITOR: The report by Thompson et al.1 indicates that the Vital Therapies extracorporeal cellular therapy (ELAD) has no impact on survival in patients with severe alcoholic hepatitis. The authors conclude that the device may work in a more carefully selected patient population. We wish to bring 2 additional points to the attention of the readership. First, we believe that perfusing mammalian liver cells with plasma instead of blood results in a hypoxic environment that diminishes cell function, regardless of the source or mass of cells used. We have addressed this in 2 recent reviews.2 We also suspect that the findings might have been entirely different had the original ELAD design been used. Second, the authors do not elaborate on reasons for failure of a device that was effective in a large animal model4 and promising in early human studies.5 We suggest that the C3A cell line, notwithstanding some metabolic differences from normal human hepatocytes, would function adequately when used in an appropriately formatted liver assist device.
No takes yet. Share an insight, caveat, or question.
Sussman et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: